- Home
- PROK vs DNMX Comparison
PROK vs DNMX Comparison
Compare PROK & DNMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.81
Company Overview
Basic Information| Metric | PROK | DNMX |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | 231 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 265.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PROK | DNMX |
|---|---|---|
| Price | $1.81 | $9.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.40 | N/A |
| AVG Volume (30 Days) | ★ 795.9K | 59.3K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.46 | $9.87 |
| 52 Week High | $7.13 | $9.99 |
Technical Indicators
Market Signals| Indicator | PROK | DNMX |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 49.33 |
| Support Level | $1.71 | $9.90 |
| Resistance Level | $2.58 | $9.99 |
| Average True Range (ATR) | 0.14 | 0.01 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 42.97 | 40.00 |
Price Performance
Historical Comparison PROK
DNMX
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About DNMX Dynamix Corporation III Class A Ordinary Shares
Dynamix Corp III is a blank check company.